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Summary
Background The ICON8 study reported no significant improvement in progression-free survival (a primary endpoint) 
with weekly chemotherapy compared with standard 3-weekly treatment among patients with epithelial ovarian cancer. 
All ICON8 patients were eligible to take part in the accompanying health-related quality-of-life study, which measured 
the effect of treatment on self-reported wellbeing, reported here.
Methods In this open-label, randomised, controlled, phase 3, three-arm, Gynecologic Cancer Intergroup (GCIG) trial 
done at 117 hospital sites in the UK, Australia, New Zealand, Mexico, South Korea, and Republic of Ireland, women 
(aged at least 18 years) with newly diagnosed, histologically confirmed International Federation of Gynecology and 
Obstetrics stage IC–IV ovarian cancer and an Eastern Cooperative Oncology Group performance status of 0–2 were 
randomly assigned (1:1:1) centrally using minimisation to group 1 (intravenous carboplatin area under the curve 
[AUC]5 or AUC6 and 175 mg/m² intravenous paclitaxel every 3 weeks), group 2 (carboplatin AUC5 or AUC6 every 
3 weeks and 80 mg/m² paclitaxel weekly), or group 3 (carboplatin AUC2 weekly and 80 mg/m² paclitaxel weekly). 
Randomisation was stratified by GCIG group, disease stage, and outcome and timing of surgery. Patients and 
clinicians were not masked to treatment assignment. Patients underwent immediate or delayed primary surgery 
according to clinicians’ choice. Patients were asked to complete European Organisation for Research and Treatment 
of Cancer QLQ-C30 and QLQ-OV28 questionnaires at enrolment, before each chemotherapy cycle, then 6-weekly up 
to 9 months, 3-monthly up to 2 years, and 6-monthly up to 5 years. Quality of life was a prespecified secondary 
outcome of the ICON8 study. Within the quality-of-life study, the co-primary endpoints were QLQ-C30 global health 
score at 9 months (cross-sectional analysis) and mean QLQ-C30 global health score from randomisation to 9 months 
(longitudinal analysis). Data analyses were done on an intention-to-treat basis. The trial is registered on ClinicalTrials.
gov, NCT01654146 and ISRCTN Registry, ISRCTN10356387, and is currently in long-term follow up.
Findings Between June 6, 2011, and Nov 28, 2014, 1566 patients were recruited into ICON8 (522 were included in 
group 1, 523 in group 2, and 521 in group 3). Baseline quality-of-life questionnaires were completed by 1438 (92%) of 
1566 patients and 9-month questionnaires by 882 (69%) of 1280 patients. We observed no significant difference in 
global health score at 9 months (cross-sectional analysis) between study groups (group 2 vs group 1, difference in 
mean score 2·3, 95% CI –0·4 to 4·9, p=0·095; group 3 vs group 1, –0·8, –3·8 to 2·2, p=0·61). Using longitudinal 
analysis, we found lower global health scores for those receiving weekly paclitaxel than for those receiving 3-weekly 
chemotherapy (group 2 vs group 1, mean difference –1·8, 95% CI –3·6 to –0·1, p=0·043; group 3 vs group 1, –2·9, 
–4·7 to –1·1, p=0·0018).
Interpretation We found no evidence of a difference in global quality of life between treatment groups at 9 months; 
however, patients receiving weekly treatment reported lower mean quality of life across the 9-month period after 
randomisation. Taken together with the lack of progression-free survival benefit, these findings do not support routine 
use of weekly paclitaxel-containing regimens in the management of newly diagnosed ovarian cancer.
Funding Cancer Research UK, Medical Research Council, Health Research Board Ireland, Irish Cancer Society, and 
Cancer Australia.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
ICON8 was an international, randomised, controlled, 
Gynecologic Cancer Intergroup (GCIG), phase 3 study to 
evaluate weekly dose-dense paclitaxel-containing chemo-
therapy compared with standard 3-weekly chemo-
therapy (carboplatin plus paclitaxel) in patients with 
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newly-diagnosed ovarian cancer. The study was prompted 
by the phase 3 JGOG-3016 trial in which weekly paclitaxel 
(80 mg/m²) in combination with 3-weekly carboplatin 
(area under the curve[AUC]6) was found to confer 
improved progression-free survival and overall survival 
when compared with standard treatment in Japanese 
patients with advanced ovarian cancer.1 As there is 
increasing evidence of pharma cogenomic distinctions 
between Asian and white populations, ICON8 was 
designed to explore whether the survival advantage 
observed in JGOG-3016 could also be observed in a 
mostly European population with ovarian cancer.2,3 
Results from ICON8 have shown that weekly, dose-dense 
paclitaxel-containing chemotherapy conferred no 
progression-free survival advantage when com pared with 
standard 3-weekly treatment.4 As a secondary endpoint of 
the main study, the effect on health-related quality of life 
(referred to as quality of life throughout this Article) was 
assessed during treatment and in follow-up. Here we 
report the quality-of-life results from the ICON8 study.
Methods
Study design and participants
ICON8 was an open-label, randomised, controlled, phase 3, 
three-arm trial done at 117 hospital sites in the UK, 
Australia, New Zealand, Mexico, South Korea, and 
Republic of Ireland (appendix pp 1–3). Detailed methods 
for ICON8 have been previously reported.4 Eligible 
patients were aged 18 years or older and had histolo-
gically confirmed, newly diagnosed high-risk International 
Feder ation of Gynecology and Obstetrics (FIGO) stage 
IC-IIA or any advanced (FIGO stage IIB-IV) epithelial 
ovarian, primary peritoneal, or fallopian tube carcinoma 
(collectively termed ovarian cancer). High-risk histologies 
included high-grade serous carcinoma, clear cell carci-
noma, or other poorly differentiated and grade III subtypes. 
Other inclusion criteria were an Eastern Cooperative 
Oncology Group (ECOG) performance status of 0–2; life 
expectancy longer than 12 weeks; adequate haematological, 
renal, and hepatic function; and able to start chemotherapy 
within 8 weeks after immediate primary debulking 
surgery. Patients were also eligible for the trial if there was 
no plan for surgery or planned delayed primary surgery 
after neoadjuvant chemotherapy. Patients had not received 
previous systemic therapy for ovarian cancer and were 
not scheduled to receive maintenance treatment after 
completion of protocol therapy. All patients gave written 
informed consent to join the trial.
Exclusion criteria included previous malignancy within 
5 years, previous or synchronous early-stage endometrial 
Research in context
Evidence before this study
We searched PubMed, MEDLINE, life science journals, and 
online books, including non-English language publications, 
from database inception until April 15, 2018, for prospective 
cohort and randomised trials using the search terms “ovarian 
cancer” and “weekly paclitaxel” and “carboplatin”. We excluded 
reviews and studies of other chemotherapy combinations or in 
different disease contexts. We selected trials in patients with 
primary ovarian cancer where health-related quality of life 
assessment was done. Our search identified three studies: 
JGOG-3016, GOG-0262, and MITO-7. 
The Japanese JGOG-3016 study reported improved survival 
outcomes with no detriment to quality of life in patients 
with newly diagnosed ovarian cancer for weekly, dose-dense, 
paclitaxel and 3-weekly carboplatin, compared with standard 
3-weekly carboplatin and paclitaxel. The GOG-0262 study 
compared similar dose schedules, but most patients also 
received bevacizumab, and the study reported no 
progression-free survival benefit and poorer quality of life 
with weekly treatment compared with 3-weekly treatment. 
The MITO-7 study compared weekly carboplatin plus weekly 
paclitaxel with 3-weekly carboplatin plus 3-weekly paclitaxel 
and reported improved quality of life with weekly treatment 
over the 9-week evaluation period. The evidence from these 
three studies was that weekly paclitaxel-containing 
treatment was superior to, or at best equivalent to, standard 
3-weekly treatment with little quality-of-life detriment to 
patients.
Added value of this study
To our knowledge, ICON8 is the largest study to date of weekly 
treatment for primary ovarian cancer. The study showed no 
progression-free survival advantage for patients receiving dose-
dense paclitaxel-containing chemotherapy compared with 
3-weekly carboplatin and paclitaxel. The quality-of-life results 
show that, although the global quality of life of patients was 
similar between the three treatment groups at 9 months, those 
receiving dose-dense paclitaxel had poorer quality of life during 
chemotherapy treatment, with more severe peripheral 
neuropathy that lasted for up to 18 months.
Patients could have either immediate primary debulking surgery 
followed by chemotherapy or upfront chemotherapy that was 
interrupted by delayed primary surgery; patients who had delayed 
surgery reported less detriment to quality of life with weekly 
treatment than did patients with immediate surgery.
Implications of all the available evidence
The contrasting results of ICON8 and JGOG-0316 support a 
differential response to dose-dense paclitaxel between Asian and 
white patients. With no progression-free survival benefit and 
poorer quality of life, the ICON8 results do not support the 
general use of weekly treatment among a primarily European 
population. However, by allowing more precise dose modulation 
and symptom management, weekly treatment might still be 
appropriate for some patients. The observed difference between 
patients who received immediate versus delayed surgery 
highlights the importance of prognosis in future studies.
See Online for appendix
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cancer, evidence of brain metastasis, and pre-existing 
sensory or motor neuropathy of grade 2 or above.
In the UK, ethical approval was granted by the London–
Chelsea research ethics committee. The trial also 
received ethical approval from appropriate national or 
local institutional review boards in other jurisdictions. 
The protocol can be found online.
Randomisation and masking
Patients were randomly assigned (1:1:1) to standard three-
weekly carboplatin and paclitaxel (group 1), three-weekly 
carboplatin and weekly dose-dense paclitaxel (group 2), 
or weekly carboplatin and weekly dose-dense paclitaxel 
(group 3; appendix p 4). Patients were randomly assigned 
with the Medical Research Council Clinical Trials Unit 
University College London randomisation telephone 
service; the method of minimisation was used with 
stratification factors of GCIG group, disease stage (FIGO 
stage IC high grade serous, clear cell, or grade III 
carcinoma; stage IIA high grade serous, clear cell, or 
grade III carcinoma; stage IIB; stage IIC; stage IIIA; 
stage IIIB; stage IIIC; stage IV), and outcome and timing 
of surgery (immediate surgery plus FIGO stage IC–III 
with no visible residual disease; immediate surgery plus 
FIGO stage IC–III with residual disease ≤1 cm; 
immediate surgery plus FIGO stage IV or IC–III with 
residual disease >1 cm; no surgery currently planned; or 
delayed primary surgery planned). Patients and clinicians 
were not masked to their allocated group.
Procedures
Patients entering the trial could have upfront debulking 
surgery before starting chemotherapy, referred to as 
immediate primary surgery, delayed primary surgery after 
at least three cycles of neoadjuvant chemotherapy, or no 
planned surgery. As with standard practice, the choice 
between immediate and delayed surgery was decided by 
patients’ local gynaecological oncology teams at multi-
disciplinary meetings. All participants started chemo-
therapy within 2 weeks of randomisation. Patients in 
group 1 received carboplatin area under the curve [AUC]5 
or AUC6 by intravenous infusion over 30–60 min and 
paclitaxel 175 mg/m² by intravenous infusion for 3 h on 
day 1 of a 21-day cycle for six cycles; patients in group 2 
received carboplatin as in group 1 and dose-fractionated 
paclitaxel 80 mg/m² by intravenous infusion for 1 h on 
days 1, 8, and 15 of a 21-day cycle for six cycles; and patients 
in group 3 received carboplatin AUC2 by intravenous 
infusion for 30–60 min on days 1, 8, and 15 and paclitaxel 
80 mg/m² by intravenous infusion for 1 h on days 1, 8, and 
15 of a 21-day cycle for six cycles. Additional details 
regarding treatment have been published.4 Protocol-
defined dose alterations (delay, reduction, or omission) 
were allowed for haematological and other toxic effects if 
deemed clinically necessary, as described previously.4
All patients were included in the quality of life study 
and invited to complete European Organisation for 
Research and Treatment of Cancer QLQ-C30 and 
QLQ-OV28 questionnaires to provide a subjective 
measure of their quality of life over the preceding 
7 days. The QLQ-C30 contains 30 items, including a 
global health status score, five function scales (physical, 
role, emotional, cognitive, and social) and nine 
symptom scales or items (fatigue, nausea or vomiting, 
pain, dyspnoea, insomnia, appetite loss, constipation, 
diarrhoea, and financial difficulties).5 The QLQ-OV28 
contains 28 items relevant to ovarian cancer, including 
abdominal or gastrointestinal symp toms, peripheral 
neuropathy, chemotherapy side-effects, hormonal or 
menopausal symptoms, body image, attitude to disease 
or treatment, and sexual functioning.6 For global health 
status and function scales, higher scores indicate better 
function (improved quality of life) but for symptom 
scales, higher scores indicate greater symptoms 
(poorer quality of life). The QLQ-C30 and QLQ-OV28 
questionnaires have undergone extensive psychometric 
validation and multiple translations and are acceptable 
to patients.5–7 We interpreted a change in global health 
score over time of more than 5 points as being clinically 
significant following the methodology of Cocks and 
King, who defined a change in the score of less than 5 
as clinically trivial.8–10
QLQ-C30 and QLQ-OV28 questionnaires were 
completed during outpatient attendances at day 1 of 
each chemotherapy cycle and during follow-up visits 
6-weekly until 9 months from randomisation, 3-monthly 
to 2 years from randomisation, and then 6-monthly 
for up to 5 years from randomisation (figure 1). Where 
possible, the questionnaires were also completed at 
6-month intervals after disease progression. Question-
naires were given to patients in paper format and 
completed without conferring with others before 
treatment administration or medical consultations. 
Centres were asked to report reasons for any missing 
questionnaires.
Outcomes
The trial had co-primary endpoints of progression-free 
survival and overall survival, which have been previously 
reported.4 A secondary outcome, quality of life, is 
reported here. The quality-of-life study comprised two co-
primary endpoints: cross-sectional analysis of QLQ-C30 
global health score 9 months after randomisation and 
longi tudinal analysis of QLQ-C30 global health score 
from randomisation to 9 months. Secondary quality-of-
life endpoints were defined from four clinically relevant 
function and symptom scores, as follows: QLQ-C30 
emotional function, QLQ-C30 social function, QLQ-C30 
fatigue, and QLQ-OV28 peripheral neuro pathy. These 
endpoints were analysed cross-sectionally at 9 months 
and longitudinally from randomisation to 9 months. 
Analyses of all other function and symptom scores 
up to 18 months after randomisation were treated as 
exploratory.
For the study protocol see 
https://www.ctu.mrc.ac.uk/
studies/all-studies/i/icon8/
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Statistical analysis
The sample size of ICON8 was determined to detect a 
hazard ratio of 0·75 in progression-free survival between 
groups 1 and 2, and groups 1 and 3, with two-sided 2·5% 
significance and 90% power. For quality of life, a 
retrospective power calculation showed that the study 
had 90% power to detect a difference between groups of 
5 points in global quality of life using the SD observed in 
group 1. The quality-of-life study adhered to the null 
hypothesis of the main ICON8 study—no expected 
difference in quality of life between the three random-
ised treatment groups. A quality-of-life expert panel 
(comprised of LH, CP, SPB, and RK), invited by the trial 
management group, convened on June 9, 2016, to define 
the primary, secondary, and exploratory endpoints.
We compared each weekly treatment group with the 
3-weekly group, following the main analysis of clinical 
endpoints (group 2 vs group 1, and group 3 vs group 1). To 
adjust for two comparisons against the same control 
group, we used a two-sided significance level of p=0·025 
to judge statistical significance in primary and secondary 
analyses. Descriptive data are presented for all other 
validated subscales of the QLQ-C30 and QLQ-OV28.
For cross-sectional comparisons of quality-of-life out-
comes at 9 months, we used analysis of covariance 
adjusted for baseline score, hence omitting data from the 
chemotherapy period. Longitudinal analyses used all data 
collected from baseline to 9 months; we estimated scores 
at scheduled data collection points from a mixed effects 
regression model with a time–treatment interaction, 
unstructured covariance, and patient level random 
effects. We then calculated the AUC for each treatment 
group from the fitted model. Results are presented as 
mean quality of life (ie, mean height of the curve) over the 
9-month period. The 9-month timepoint was chosen as it 
represents a period of good quality of life for most 
patients—few will have had disease progression, and 
most will have completed treatment some months earlier. 
It is also the timepoint in ICON8 at which follow-up, and 
hence data collection, changed from 6-weekly to 
3-monthly. The co-primary endpoints of cross-sectional 
and longitudinal changes in global health score are 
complementary—longitudinal analysis compares patient 
experience across the whole 9-month period and cross-
sectional analysis compares scores at the 9-month 
timepoint. Thus, longitudinal analysis makes better use 
of the data and is the preferred method, whereas cross-
sectional analysis provides a post-treatment snapshot.
For patients who had neo-adjuvant chemotherapy and 
underwent delayed primary surgery, chemo therapy 
cycles 4 to 6 and the end of treatment visit were around 
4 weeks later than equivalent visits in the immediate 
surgery group. Therefore, quality-of-life data were 
ordered by visit number rather than date.
Three post-hoc analyses were done: analysis of the 
primary and secondary outcomes separately for im-
mediate surgery and delayed surgery patients (including 
a comparison of baseline quality of life scores), a 
comparison of peripheral neuropathy scores from self-
reported quality-of-life data with neuropathy adverse 
event data from clinicians (according to Common 
Terminology Criteria for Adverse Events version 4.0),4 
and analysis of self-reported peripheral neuropathy 
scores 18 months after randomisation.
We assessed the potential effect of missing data on the 
co-primary outcome using imputation to model the 
following scenarios: scenario 1, a global score of 0 was 
imputed for patients who died within 9 months of 
enrolment; scenarios 2–4, all patients alive and without 
progression at 9 months but missing quality-of-life data 
were assigned a score, starting respectively with the 
mean 9-month score, then the mean score minus 
10 points, then mean minus 20; scenario 5, a global score 
of 0 was imputed for patients who died within 9 months, 
all other patients (including those with disease pro-
gression) with a baseline global quality-of-life score but 
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Figure 1: Timing of quality-of-life questionnaires
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missing their 9-month global quality-of-life score were 
assigned the mean 9-month score. The rationale for 
scenarios 2–4 was that patients might have missed sub-
mitting their questionnaires due to illness, in which case 
a lower quality of life would be expected.
All analyses were done on an intention-to-treat basis 
with Stata version 15.0. The trial is registered on 
ClinicalTrials.gov, NCT01654146 and ISRCTN Registry, 
ISRCTN10356387.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. SPB, ECJ, ARC, RK, and ADC had full access 
to the quality-of-life data in the study. The trial 
management group had final responsibility for the 
decision to submit for publication.
Results
Between June 6, 2011, and Nov 28, 2014, 1566 patients 
were recruited into ICON8 (522 were included in group 1, 
523 in group 2, and 521 in group 3). Baseline 
characteristics are described elsewhere.4 All patients 
were invited to partici pate in the quality-of-life study, and 
1540 patients com pleted 17 515 quality-of-life question-
naires. 9 months after randomisation, quality-of-life data 
were expected from 1280 patients in follow-up without 
disease progression; 39 patients had died, 230 were alive 
after progression, and 17 had withdrawn or been lost to 
follow-up without progression. Baseline questionnaires 
were completed by 1438 (92%) of 1566 patients and 
9-month questionnaires by 882 (69%) of 1280 patients 
(table 1). 828 (65%) of 1280 patients who could have 
contributed quality-of-life data at 9 months had both 
baseline and 9-month data and were included in cross-
sectional analyses of primary and secondary outcomes.
At the 9-month timepoint we found no significant 
difference in QLQ-C30 global health score between the 
three treatment groups with cross-sectional analysis 
(group 2 vs group 1, n=555, mean difference 2·3, 95% CI 
–0·4 to 4·9, p=0·094; group 3 vs group 1, n=522, mean 
difference –0·8, –3·8 to 2·2; p=0·61; table 2). We 
observed an improvement in mean global health score 
from baseline to 9 months post-random isation across the 
study population (figure 2), although a fall in global 
health score was observed during chemotherapy in all 
three treatment groups. With longitudinal analysis, 
mean global health scores across the 9-month period 
were lower among patients in the weekly treatment 
groups, with a significant difference between group 3 
and group 1 (group 2 vs group 1, 926 patients had global 
health score at baseline, and at least one score between 
baseline and 9 months, mean difference –1·8, 95% CI 
–3·6 to –0·1, p=0·043; group 3 vs group 1, n=915 patients 
had global health score at baseline, and at least one score 
between baseline and 9 months, mean difference –2·9, 
–4·7 to –1·1; p=0·0018; table 2). These results indicated 
poorer global health for patients who received weekly 
paclitaxel-containing treatment than for those who 
received 3-weekly chemotherapy but did not meet the 
threshold for clinical significance.
We observed evidence of better emotional functioning 
(QLQ-C30) with weekly treatment (group 3) than with 
3-weekly treatment (group 1) using cross-sectional 
analysis; however, it did not meet the threshold for 
clinical significance (table 3; figure 2). Longitudinal 
analysis revealed no significant differences in emotional 
functioning between study groups (table 3; figure 2). 
We found no difference in social functioning (QLQ-C30) 
between treatment groups using either cross-sectional 
or longitudinal analyses (table 3; figure 2). We observed 
no difference in fatigue (QLQ-C30) between groups by 
cross-sectional analysis; although fatigue scores were 
significantly different between the weekly (group 2) and 
3-weekly (group 1) treatment groups by longitudinal 
analysis, they did not meet the threshold for clinical 
signifi cance (table 3; figure 2). By cross-sectional 
analysis, peripheral neuropathy scores (QLQ-OV28) 
were statisti cally and clinically significantly different 
between group 2 and group 1; however, there was no 
difference by longitudinal analysis (table 3; figure 2). 
Group 1 Group 2 Group 3
Patients Quality of 
life
Patients Quality of 
life
Patients Quality of 
life
Baseline 522 475 (91%) 523 482 (92%) 521 481 (92%)
Chemotherapy
Start of cycle 3 513 428 (83%) 515 425 (83%) 508 403 (79%)
Start of cycle 5 489 376 (77%) 502 357 (71%) 477 366 (77%)
Follow-up
6 weeks post treatment 456 259 (57%) 484 251 (52%) 455 249 (55%)
9 months post treatment 410 288 (70%) 446 306 (69%) 424 288 (68%)
Data are n or n (%). Group 1=standard three-weekly carboplatin and paclitaxel. Group 2=three-weekly carboplatin and 
weekly dose-dense paclitaxel. Group 3=weekly carboplatin and weekly dose-dense paclitaxel.
Table 1: Completeness of quality-of-life data, by randomly allocated group and time
Group 1 (n=410) Group 2 (n=446) Group 3 (n=424)
Patients with global health score data at 
baseline and 9 months
264 (64%) 291 (65%) 258 (61%)
Global health score
Baseline 61·7 (22·1) 60·4 (23·0) 60·3 (22·8)
9 months 74·8 (17·5) 76·9 (15·8) 73·9 (19·1)
Mean score over 9 months (SE)* 70·5 (0·9) 68·7 (1·0) 67·7 (1·0)
Difference in 9-month score vs group 1† ·· 2·3 (–0·4 to 4·9); 
p=0·094
–0·8 (–3·8 to 2·2); 
p=0·61
Difference in mean score vs group 1 ·· –1·8 (–3·6 to –0·1); 
p=0·043
–2·9 (–4·7 to –1·1); 
p=0·0018
Data are n (%), mean (SD), or mean (95% CI), unless otherwise indicated. Group 1=standard three-weekly carboplatin 
and paclitaxel. Group 2=three-weekly carboplatin and weekly dose-dense paclitaxel. Group 3=weekly carboplatin and 
weekly dose-dense paclitaxel. *From area under the curve, calculated from mixed effects regression model. †Adjusted 
for baseline.
Table 2: QLQ-C30 global health score during first 9 months of treatment
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The timing of neuropathy differed between groups 
(figure 2).
Exploratory cross-sectional analyses of the other 
QLQ-C30 and QLQ-OV28 subscales showed that differ-
ences between the three randomised groups were 
generally small (appendix pp 5–6). We did not analyse 
data on sexual function since more than 80% of patients 
reported that they were sexually inactive at baseline.
A post-hoc analysis of peripheral neuropathy scores 
showed that, for patients who remained in follow-up 
without progression, high scores were still observed 
18 months after randomisation for all treatment groups 
(appendix p 7). There was a statistically and clinically 
significant difference between group 2 and group 1 
(n=298 with neuropathy score at baseline and 18 months, 
mean difference 10·7, 95% CI 4·2 to 17·2; p=0·0012) but 
not group 3 and group 1 (n=316 patients in group 1 or 
group 3 with neuropathy score at baseline and 18 months, 
4·8, –0·9 to 10·4; p=0·096) by cross-sectional analysis. 
Longi tudinal analysis did not show significant differences 
between the groups (group 2 vs group 1, n=898 patients 
with neuropathy score at baseline and at least one 
neuropathy score between baseline and 18 months, mean 
difference 2·5, 95% CI –1·2 to 6·1, p=0·18; group 3 vs 
group 1, n=901 patients with neuropathy score at baseline 
and at least one neuropathy score between baseline and 
18 months, 2·5, –1·2 to 6·1, p=0·19).
Post-hoc analyses were done to investigate differences 
in quality of life related to timing of surgery (immediate 
primary surgery vs delayed primary surgery; appendix 
pp 8–10). Baseline characteristics by surgery timing are 
shown in the appendix (p 11). QLQ-C30 global health 
score at baseline was significantly lower among patients 
who had delayed surgery (n=714) than those who had 
immediate surgery (n=675) (mean 56·2 [SD 24·3] vs 
mean 61·7 [21·6]; p<0·0001). Baseline emotional 
function (delayed surgery, n=716, mean 68·6 [SD 23·6]; 
immediate surgery, n=673, mean 73·6 [21·5]; p<0·0001) 
and fatigue (delayed surgery, n=720, mean 42·3 [SD 27·0]; 
immediate surgery, n=679, mean 35·8 [22·9]; p<0·0001) 
were also significantly worse among patients who had 
delayed surgery, but we observed no difference in 
baseline scores for social function or peripheral neuro-
pathy between patients with different surgery timings 
(data not shown). For patients who had immediate 
surgery, longi tudinal analysis of the global health score 
over 9 months mirrored that in the overall study 
population (appendix pp 8–10). However, among patients 
who had delayed surgery the difference between 
treatment groups was smaller than it was in the overall 
study population (appendix pp 8–10).
We did a post-hoc analysis to assess concordance 
between self-reported peripheral neuropathy from the 
quality-of-life questionnaires and clinician-assessed 
peripheral neuropathy reported during the treatment 
period; there was good agreement between the measures 
(appendix p 12). Sensitivity analyses to assess the 
potential effect of missing data did not alter our 
interpretation of the data (appendix p 13).
Discussion
The primary outcome of this study showed no difference 
between treatment groups in global health score at 
9 months compared with baseline. However, longitudinal 
analysis revealed lower global health scores during 
chemotherapy for those in the weekly treatment groups 
than for those in the 3-weekly treatment group, which, 
although statistically significant, was of marginal clini-
cal significance. These findings indicate that patients 
receiving weekly paclitaxel-containing chemotherapy 
had slower improvement in their overall quality of life 
during treatment itself, but recovered to a similar level to 
those receiving 3-weekly treatment at 9 months. Other 
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Figure 2: Primary and secondary quality-of-life endpoints
For global health status and function scales (QLQ-C30 global health status, emotional function, and social 
function), higher scores indicate better function (improved quality of life) but for symptom scales (QLQ-C30 
fatigue and QLQ-OV28 peripheral neuropathy), higher scores indicate greater symptoms (poorer quality of life). 
Error bars represent 95% CIs. The number of expected questionnaires and received questionnaires is reported in 
the appendix (p 5).
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secondary outcomes revealed slightly worse fatigue and 
more persistent peripheral neuropathy in the weekly 
paclitaxel-containing groups than in the 3-weekly group, 
although other quality-of-life subscores were similar 
between the study groups. Patients in the 3-weekly 
treatment group had an earlier onset of, but more rapid 
improvement in, peripheral neuropathy symptoms after 
completion of chemotherapy than did patients in the 
weekly treatment groups. By contrast, symptoms of 
peripheral neuropathy developed more gradually for 
patients in the weekly treatment groups compared with 
the 3-weekly treatment group but persisted beyond the 
end of treatment and into the follow-up period.
The observed differences in these quality-of-life sub-
scores are probably due to paclitaxel exposure. As with 
the JGOG-3016 and GOG-0262 studies,11,12 patients in 
group 2 and group 3 of ICON8 received up to 80 mg/m² 
of paclitaxel per week, equivalent to 240 mg/m² per cycle. 
In these three studies, peripheral neuropathy was worse 
in the weekly treatment groups than in the 3-weekly 
treatment group. By contrast, in the MITO-7 study,13 a 
lower weekly dose of 60 mg/m² paclitaxel was admin-
istered in the weekly group (equivalent to 180 mg/m² per 
cycle) and lower neuropathy scores were reported in the 
weekly group compared to those in the 3-weekly group 
(who received a similar per cycle dose of paclitaxel; 
appendix p 14). These findings suggest that peripheral 
neuropathy could be caused by cumulative exposure to 
paclitaxel rather than dosing intensity, although the exact 
mechanism of taxane neurotoxicity remains incompletely 
understood.
The large size of ICON8 allowed comparison between 
the quality-of-life trajectories of patients who had 
immediate primary surgery and delayed primary surgery. 
As the choice of upfront or delayed surgery was not 
randomly assigned, patients with more advanced-stage 
disease and poorer perfor mance status were selected for 
upfront chemo therapy and delayed surgery, intended to 
reduce their anaesthetic risk and allow chemotherapy 
downstaging. Overall, patients who had delayed surgery 
had a larger incre mental improvement in quality of life 
from randomisation to 9 months than did patients with 
immediate surgery, although having started from a lower 
point this result might have been expected. Their nadir 
quality-of-life score occurred at randomisation and 
improved during chemotherapy (with a slight fall at the 
time of interval surgery). The treatment break imposed 
by delayed surgery might also have lessened the 
cumulative effect of chemotherapy in these patients. By 
contrast, patients who had immediate surgery entered 
ICON8 having recovered from surgery and with better 
quality of life; although they had a quality-of-life nadir 
following chemotherapy (at around 18 weeks), their 
quality of life recovered to the same level as those in the 
delayed surgery group at 9 months. In patients who had 
immediate surgery, treatment-related fatigue and global 
quality-of-life were significantly (and clinically) worse in 
the weekly paclitaxel-containing groups than in the 
3-weekly treatment group.
To address the immediate and long-term effect of 
treatment on quality of life in ICON8, we chose an 
intensive method of quality-of-life data collection during 
treatment and in post-treatment follow-up. Thus, 
questionnaires were completed at every treatment cycle 
rather than at the beginning, middle, and end of 
treatment. We recommend this close method of tracking 
of quality of life, along with longitudinal rather than 
Group 1 (n=410) Group 2 (n=446) Group 3 (n=424)
Emotional function
Patients with emotional function data 
at baseline and 9 months
265 (65%) 290 (65%) 261 (62%)
Baseline* 73·1 (20·9) 74·8 (20·7) 70·5 (23·5)
9 months 80·0 (20·6) 82·9 (19·6) 82·8 (19·6)
Mean score over 9 months (SE)† 79·0 (0·8) 80·6 (0·9) 80·5 (0·9)
Difference in 9-month score vs group 1‡ ·· 2·0 (–1·0 to 5·0); 
p=0·19
3·7 (0·5 to 6·8); 
p=0·024
Difference in mean score vs group 1 ·· 1·6 (–0·2 to 3·5); 
p=0·082
1·6 (–0·3 to 3·4); 
p=0·10
Social function
Patients with social function data at 
baseline and 9 months
265 (65%) 290 (65%) 261 (62%)
Baseline* 63·5 (30·5) 65·4 (30·1) 61·1 (31·3)
9 months 82·8 (22·2) 83·7 (23·7) 84·1 (22·5)
Mean score over 9 months (SE)† 78·3 (1·2) 76·5 (1·3) 76·8 (1·3)
Difference in 9-month score vs group 1‡ ·· 0·4 (–3·4 to 4·1); 
p=0·85
1·7 (–1·9 to 5·3); 
p=0·36
Difference in mean score vs group 1 ·· –1·8 (–4·3 to 0·7); 
p=0·15
–1·5 (–4·0 to 1·0); 
p=0·24
Fatigue
Patients with fatigue data at baseline 
and 9 months
269 (66%) 292 (65%) 266 (63%)
Baseline* 36·3 (25·4) 36·8 (24·9) 38·1 (24·8)
9 months 23·7 (19·4) 22·1 (21·0) 22·5 (20·2)
Mean score over 9 months (SE)† 32·7 (1·0) 35·4 (1·1) 34·8 (1·1)
Difference in 9-month score vs group 1‡ ·· –1·8 (–4·8 to 1·3); 
p=0·26
–1·8 (–4·9 to 1·3); 
p=0·25
Difference in mean score vs group 1 ·· 2·7 (0·6 to 4·8); 
p=0·011
2·1 (–0·1 to 4·2); 
p=0·057
Peripheral neuropathy
Patients with peripheral neuropathy 
data at baseline and 9 months
260 (63%) 280 (63%) 260 (61%)
Baseline* 5·1 (13·4) 2·4 (8·0) 4·1 (13·1)
9 months 27·0 (25·7) 34·0 (31·0) 31·8 (28·3)
Mean score over 9 months (SE)† 32·9 (1·3) 31·8 (1·5) 31·2 (1·5)
Difference in 9-month score vs group 1‡ ·· 8·6 (3·8 to 13·3); 
p<0·0001
5·2 (0·5 to 9·8); 
p=0·028
Difference in mean score vs group 1 ·· –1·2 (–4·2 to 1·8); 
p=0·45
–1·8 (–4·8 to 1·3); 
p=0·25
Data are n (%), mean (SD), or mean (95% CI) unless otherwise indicated. Group 1=standard three-weekly carboplatin 
and paclitaxel. Group 2=three-weekly carboplatin and weekly dose-dense paclitaxel. Group 3=weekly carboplatin and 
weekly dose-dense paclitaxel. *Patients with quality-of-life data at baseline and 9 months. †From area under the curve, 
calculated from mixed effects regression model. ‡Adjusted for baseline.
Table 3: QLQ-C30 emotional function, social function, fatigue symptom, and QLQ-OV28 peripheral 
neuropathy symptom scores during first 9 months of treatment
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cross-sectional methods of analysis, to more accurately 
reflect changes over time. Alternatively, standardised, 
continuous patient-reported outcome measures can be 
implemented to provide more reliable monitoring of the 
longer-term toxicities that affect patient wellbeing.12 
Because of the differences between non-randomised 
patients undergoing immediate or delayed surgery, we 
recommend that these two surgical groups are analysed 
separately in future quality-of-life studies.
To our knowledge, ICON8 provides the largest and most 
detailed quality-of-life dataset of any neoadjuvant ovarian 
cancer trial. A limitation of the study is the loss of quality-
of-life data due to patients who did not complete or return 
their questionnaires, which poten tially introduced bias 
against those with more severe symptoms who might 
have been less able or willing to comply. However, we did 
not observe a difference in data return between the 
treatment groups, indicating this was unlikely to be a 
consequence of a specific regimen. Questionnaire com-
pliance was favourable compared with other similar 
studies; baseline quality-of-life questionnaires were com-
pleted by 92% of patients in ICON8 compared with 
63·9% and 75% in the JGOG-3016 and MITO-7 studies, 
respectively. Although we noted numerous changes in 
quality-of-life subscores across the groups, many did not 
reach clinical significance. We selected a change in score 
of 5 points as being clinically significant, based on studies 
of snapshot rather than longitudinal quality-of-life com-
parisons. Hence, in this context, the cutoff is exploratory 
and possibly too stringent for defining the clinical 
significance of the quality-of-life subscales. There might 
also be clinical reasons for the lack of clinical significance 
observed, such as different causalities causing similar 
symptoms. For example, patients with bulky, unresected 
tumours at baseline might report ongoing fatigue that is 
replaced by drug-related fatigue once chemotherapy is 
underway. Additionally, response shift is a limitation of 
quality-of-life studies, whereby patients adapt to and 
therefore underreport symptoms over time.14
As the main ICON8 study revealed no progression-free 
survival advantage for weekly paclitaxel-containing 
regimens, our quality-of-life data do not support its use 
in favour of standard 3-weekly carboplatin and paclitaxel 
after upfront surgery in ovarian cancer. However, our 
finding of no quality of life detriment between the groups 
among patients who had delayed surgery suggests that, 
in those unsuitable for upfront surgery, 3-weekly and 
weekly schedules might be equivocal. In patients who 
have delayed surgery, who are likely to be in poorer 
health, the weekly scheduling of both carboplatin and 
paclitaxel allows more careful dosing modulation and 
symptom management than 3-weekly dosing, and is 
equivalent to 3-weekly dosing in terms of its effect on 
global quality of life.
In conclusion, for patients undergoing upfront surgery, 
weekly paclitaxel-containing chemotherapy should not 
replace 3-weekly carboplatin and paclitaxel as the 
standard of care for newly diagnosed ovarian cancer, 
since it neither improves progression-free survival nor is 
associated with improved quality of life.
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